Recent Updates
Recently added Catalysts
BIOA Negative Sentiment Score: 25/100

BioAge Labs, Inc. Class Action: The Gross Law Firm Reminds BioAge Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 – BIOA

Key Takeaway: The Gross Law Firm has announced a pending class action lawsuit on behalf of shareholders of BioAge Labs, Inc. (BIOA). This follows BioAge's discontinuation of its STRIDES Phase 2 trial for azelaprag due to safety concerns that emerged shortly after the company went public. The stock saw a significant decline in value as a result of the announcement, falling from $20.09 to $4.65. The law firm encourages shareholders to register for potential participation in the lawsuit, with a lead plaintiff deadline set for March 10, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • BioAge's stock price plummeted from $20.09 to $4.65 following the trial discontinuation.
  • The discontinuation of the STRIDES Phase 2 trial raises serious safety concerns.
  • Allegations of misleading information related to azelaprag's potential in obesity therapy.

Full Press Release Details

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA).
Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to BioAge’s registration statement for the initial public offering held on or about September 26, 2024.
ALLEGATIONS: According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs. Following this news, BioAge’s stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.
DEADLINE: March 10, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=132038&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of BIOA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 10, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the deadline for BioAge Labs shareholders to register?

The registration deadline for BioAge Labs shareholders is March 10, 2025.

Why did BioAge's stock price drop significantly?

BioAge's stock price fell after announcing the discontinuation of its Phase 2 trial for azelaprag due to safety concerns.

Can shareholders participate without being a lead plaintiff?

Yes, shareholders can participate in the recovery without needing to be appointed as lead plaintiff.

What happens after registering for the class action?

After registering, shareholders will receive updates through portfolio monitoring software.

What allegations are made against BioAge Labs?

The allegations include misleading investors about the safety of azelaprag before the IPO.

Last updated: Feb 26, 2025